TMO vs PFE vs RVTY Stock Comparison

Thermo Fisher Scientific, Pfizer and Revvity Prices as of Nov 13, 2026 Peers: Industry group
PFE Pfizer Inc
$28.90 -1.1% 1M +12.1% 1Y
Market cap
$165.02B
P/E
40.9x
Revenue (TTM)
$63.63B
Div. yield
0.06%
Pharmaceuticals Healthcare
6 wins
RVTY Revvity, Inc.
$154.52 +1.5% 1M +65.4% 1Y
Market cap
$16.69B
P/E
65.9x
Revenue (TTM)
$2.94B
Div. yield
0.00%
Life Sciences Tools Healthcare
1 win

Head to Head

12 decided of 12

Pfizer leads on 6 of the 12 questions below (Pfizer 6, Thermo Fisher Scientific 5, Revvity 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionTMOPFERVTYLeader
Larger companyMarket capitalisation $257.27B $165.02B $16.69B TMO
Cheaper on earningsLower P/E, profitable companies only 36.4x 40.9x 65.9x TMO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 27.0x 9.8x 29.9x PFE
Faster revenue growthRevenue growth, trailing twelve months +8.3% +1.3% +4.6% TMO
More profitableNet margin, trailing twelve months 14.9% 6.3% 8.6% TMO
Better return on capitalReturn on invested capital 8.0% 12.3% 3.3% PFE
Less leveragedLower net debt / EBITDA 3.1x 1.9x 2.6x PFE
Higher dividend yieldTrailing dividend yield 0.00% 0.06% 0.00% PFE
Better 1-year returnPrice return, last 12 months +20.7% +12.1% +65.4% RVTY
Better 5-year returnAnnualised price return, 5 years +2.0%/yr -10.3%/yr -3.4%/yr TMO
Less volatileAnnualised volatility, 1 year 30.7% 21.7% 41.2% PFE
Higher overall scoreMean of the five percentile scores vs peers 60/100 68/100 61/100 PFE

Percentile Scorecard

TMOPFERVTY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTMOPFERVTY
Valuation 62 #94 of 243 95 #37 of 660 72 #70 of 243
Growth 41 #136 of 228 37 #392 of 619 38 #141 of 228
Profitability 82 #40 of 222 92 #50 of 595 81 #43 of 222
Financial Health 31 #172 of 248 25 #516 of 683 56 #110 of 248
Shareholder Returns 82 #29 of 158 91 #44 of 459 56 #70 of 158
Overall 60 68 61
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • PFE ranked among 695 companies in Pharmaceuticals and Biotechnology
  • RVTY ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTMOPFERVTYSPY
1 month +4.0%-1.1%+1.5% -2.0%
3 months +19.1%+7.9%+32.2% -2.8%
6 months +59.7%+14.1%+64.4% +2.0%
Year to date +20.8%+16.1%+59.7% +10.6%
1 year +20.7%+12.1%+65.4% +12.2%
3 years +52.5%-1.2%+75.9% +68.1%
3 years, per year +15.1%-0.4%+20.7% +18.9%
5 years +10.2%-41.9%-15.8% +61.4%
5 years, per year +2.0%-10.3%-3.4% +10.1%
10 years +362.9%-11.3%+203.6% +248.5%
10 years, per year +16.6%-1.2%+11.7% +13.3%

Risk

MeasureTMOPFERVTYSPY
Volatility, 1Y 30.7%21.7%41.2% 13.6%
Downside volatility, 1Y 29.2%21.9%37.1% 13.9%
Beta vs S&P 500, 1Y 0.710.261.22 1.00
Return / volatility, 1Y 0.670.561.59 0.90
Max drawdown, 5Y -41.5%-64.8%-59.2% -25.4%
From 52-week high -3.0%-6.1%-6.8% -3.2%
52-week high $721.63$30.79$165.78 $779.14
52-week low $438.34$23.67$82.26 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTMOPFERVTY
P/E now vs peer median 36.6xmedian 26.5x 40.8xmedian 17.0x 68.1xmedian 26.5x
P/S now vs peer median 5.5xmedian 2.7x 2.6xmedian 8.4x 5.9xmedian 2.7x
EV/EBITDA now vs peer median 25.5xmedian 18.4x 8.2xmedian 14.6x 24.4xmedian 18.4x
P/FCF now vs peer median 34.2xmedian 25.4x 14.0xmedian 19.0x 28.7xmedian 25.4x
P/B now vs peer median 4.7xmedian 2.5x 1.8xmedian 2.0x 2.4xmedian 2.5x
PEG now vs peer median 4.84median 0.98 -1.47median 0.43 -2.46median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTMOPFERVTY
Revenue $47.35B $63.63B $2.94B
Gross profit $19.45B $46.69B $1.64B
Operating income $8.47B $19.40B $372.09M
Net income $7.09B $4.06B $253.20M
Free cash flow $7.60B $11.79B $601.13M
R&D $1.40B $11.52B $213.15M
EPS (diluted) $19.06 $0.70 $2.26
Cash & equivalents $5.46B $1.82B $592.80M
Total debt $41.37B $62.67B $2.63B
Shares (diluted) 371.00M 5.75B 111.83M
Enterprise value $233.79B $112.37B $13.29B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTMOPFERVTY
P/E 36.6x 40.8x 68.1x
P/FCF 34.2x 14.0x 28.7x
P/Operating cash flow 27.8x 11.6x 25.9x
P/S 5.5x 2.6x 5.9x
P/B 4.7x 1.8x 2.4x
P/Tangible book 7.1x 3.8x 3.4x
EV/EBITDA 25.5x 8.2x 24.4x
EV/EBIT 34.8x 11.0x 51.8x
EV/Revenue 6.2x 3.3x 6.6x
EV/FCF 38.8x 18.1x 32.1x
EV/Operating cash flow 31.6x 15.0x 28.9x
PEG (3Y EPS CAGR) 4.84 -1.47 -2.46

Growth

14 metrics
MetricTMOPFERVTY
Revenue growth (1Y) 8.3% 1.3% 4.6%
Revenue CAGR (3Y) 2.9% -3.2% 1.7%
Gross profit growth (1Y) 7.8% 1.3% 5.8%
Gross profit CAGR (3Y) 4.0% 2.7% 1.2%
Operating income growth (1Y) 12.8% -4.3% 2.3%
Operating income CAGR (3Y) 7.2% 7.4% 1.0%
Net income growth (1Y) 7.9% -58.9% 6.6%
Net income CAGR (3Y) 6.2% -27.2% -30.1%
EPS growth (1Y) 9.7% -59.2% 10.1%
EPS CAGR (3Y) 7.6% -27.7% -27.6%
Operating cash flow growth (1Y) 21.9% 8.4% 14.4%
Operating cash flow CAGR (3Y) 4.5% 5.6% 49.3%
Free cash flow growth (1Y) 24.3% 13.6% 19.1%
Free cash flow CAGR (3Y) 5.1% 13.0% 44.7%

Profitability

14 metrics
MetricTMOPFERVTY
Gross margin 41.1% 73.4% 55.9%
EBITDA margin 24.4% 40.7% 26.8%
Operating margin 17.9% 30.5% 12.6%
Pretax margin 16.7% 6.7% 9.6%
Net margin 14.9% 6.3% 8.6%
FCF margin 16.0% 18.5% 20.4%
Operating cash flow margin 19.7% 22.3% 22.7%
Return on equity 13.2% 4.7% 3.5%
Return on assets 6.2% 2.0% 2.2%
Return on invested capital 8.0% 12.3% 3.3%
Return on capital employed 8.5% 11.3% 3.4%
Asset turnover 0.4x 0.3x 0.2x
Cash conversion (OCF / net income) 1.3x 3.5x 2.6x
Stock comp / revenue 0.7% 1.7% 0.9%

Financial Health

11 metrics
MetricTMOPFERVTY
Debt / assets 36.2% 30.6% 22.9%
Debt / equity 0.8x 0.7x 0.4x
Net debt / EBITDA 3.1x 1.9x 2.6x
Debt / FCF 5.4x 5.3x 4.4x
Liabilities / assets 52.1% 56.4% 36.7%
Equity / assets 47.9% 43.6% 63.3%
Interest coverage 12.0x – 4.2x
Current ratio 1.8x 1.4x 2.7x
Quick ratio 1.2x 0.9x 1.9x
Cash ratio 0.4x 0.4x 0.8x
Altman Z-score 4.18 2.34 3.69

Shareholder Returns

7 metrics
MetricTMOPFERVTY
Dividend yield 0.3% 6.0% 0.2%
Net buyback yield 1.6% – 1.5%
Shareholder yield 1.8% 6.0% 1.7%
Payout ratio (earnings) 9.5% 241.2% 12.4%
Payout ratio (FCF) 8.9% 83.1% 5.2%
Dividend growth (1Y) 8.0% 0.9% -5.9%
Dividend CAGR (3Y) 10.1% 2.2% -6.2%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTMOPFERVTY
Forward P/E 27.0xFY2026 9.8xFY2026 29.9xFY2026
EPS, next fiscal year $25.92FY2026 $2.95FY2026 $5.16FY2026
EPS growth, next FY +13.3%FY2026 -8.4%FY2026 +2.0%FY2026
EPS growth, the year after +2.2% -5.8% +11.0%
Revenue, next fiscal year $50.12BFY2026 $61.46BFY2026 $3.00BFY2026
Revenue growth, next FY +12.5%FY2026 -1.8%FY2026 +4.8%FY2026
Revenue growth, the year after -2.7% +4.0% -2.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTMOPFERVTY
Held by institutions 90.2% 66.9% 100.0%
Institutions holding 2,627 2,842 547
Change in shares held, QoQ +0.8% +2.0% -1.3%
Institutions buying 1,145 1,327 303
Institutions selling 1,145 1,206 161
Buyers to sellers 1.00 1.10 1.88

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

TMOPFERVTY
TMO 1.00 0.24 0.72
PFE 0.24 1.00 0.15
RVTY 0.72 0.15 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, TMO, PFE and RVTY?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Thermo Fisher Scientific (TMO) $257.27B, Pfizer (PFE) $165.02B, Revvity (RVTY) $16.69B.

Which stock is cheaper, TMO, PFE and RVTY?

Thermo Fisher Scientific (TMO) trades on the lowest price-to-earnings ratio (Thermo Fisher Scientific (TMO) 36.4x, Pfizer (PFE) 40.9x, Revvity (RVTY) 65.9x). On next year's consensus earnings, Pfizer (PFE) is cheapest (Thermo Fisher Scientific (TMO) 27.0x, Pfizer (PFE) 9.8x, Revvity (RVTY) 29.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Thermo Fisher Scientific (TMO) +8.3%, Pfizer (PFE) +1.3%, Revvity (RVTY) +4.6%.

Which company is more profitable?

Thermo Fisher Scientific (TMO) has the highest net margin (Thermo Fisher Scientific (TMO) 14.9%, Pfizer (PFE) 6.3%, Revvity (RVTY) 8.6%). On return on invested capital, Pfizer (PFE) leads (Thermo Fisher Scientific (TMO) 8.0%, Pfizer (PFE) 12.3%, Revvity (RVTY) 3.3%).

Which stock has performed better?

Over the past year Revvity (RVTY) returned the most: Thermo Fisher Scientific (TMO) +20.7%, Pfizer (PFE) +12.1%, Revvity (RVTY) +65.4%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Thermo Fisher Scientific (TMO) +2.0%/yr, Pfizer (PFE) -10.3%/yr, Revvity (RVTY) -3.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Pfizer (PFE) has the highest dividend yield: Thermo Fisher Scientific (TMO) 0.00%, Pfizer (PFE) 0.06%, Revvity (RVTY) 0.00%.

Which stock is riskier?

By one-year price volatility, Pfizer (PFE) has been the steadiest (Thermo Fisher Scientific (TMO) 30.7%, Pfizer (PFE) 21.7%, Revvity (RVTY) 41.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, TMO, PFE and RVTY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Pfizer (PFE) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.